Service de Cardiologie, GCS ES Axium Rambot, 21, Avenue Alfred Capus, 13 090 Aix en Provence, France.
Service de Cardiologie, GCS ES Axium Rambot, 21, Avenue Alfred Capus, 13 090 Aix en Provence, France.
Cardiovasc Revasc Med. 2020 Jun;21(6):785-789. doi: 10.1016/j.carrev.2019.10.007. Epub 2019 Oct 18.
To report procedural and 1-year outcomes following COBRA PzF NCS implantation in a routine daily setting with high bleeding risk (HBR) patients treated with clopidogrel as mono antiplatelet therapy (MAPT).
This is a prospective, consecutive, observational study in HBR patients who underwent PCI with COBRA PzF NCS and treated with clopidogrel alone at discharge. The primary endpoint was definite stent thrombosis at one month. The secondary endpoint was MACE (Cardiac Death, myocardial infarction (MI), target lesion revascularization (TLR)) at 12 months.
From October 2015 to December 2018, 77 patients with 120 lesions were enrolled and treated. Mean age was 78.7 ± 8.89 years, 58.5% men and 18.2% had ACS. Patients included had a minimum of 2.0 inclusion LEADERS FREE criteria. Angiographic success was achieved in all cases. The primary endpoint occurred in 0%, no stent thrombosis was occurred. MACE at 12-months (available for 52 patients) was 3.8% including cardiac death 0%, MI 0% and TLR 3.8%. No severe bleeding events (BARC3-5) or stroke or late stent thrombosis were noted.
Clopidogrel as MAPT after COBRA PzF NCS implantation in HBR patients is feasible and an attractive option. One-year follow-up was associated with excellent clinical outcomes and should be confirmed with large randomised study.
This is prospective registry of high bleeding risk patients treated with the COBRA PzF NCS and MAPT at discharge. The primary end point demonstrated no stent thrombosis. The rate of major cardiac adverse events (a composite of cardiovascular death, myocardial infarction and target lesion revascularisation) at 1 year was 3.8%. No severe bleeding events, stroke or late stent thrombosis were noted. One-year follow-up was associated with good clinical outcomes and compared favorably with current devices.
报告在高出血风险（HBR）患者中，在常规日常环境下使用氯吡格雷作为单一抗血小板治疗（MAPT）进行 COBRA PzF NCS 植入后的程序和 1 年结果。
这是一项前瞻性、连续、观察性研究，纳入了接受 COBRA PzF NCS 经皮冠状动脉介入治疗（PCI）并在出院时单独使用氯吡格雷治疗的 HBR 患者。主要终点是 1 个月时的明确支架血栓形成。次要终点是 12 个月时的 MACE（心脏死亡、心肌梗死（MI）、靶病变血运重建（TLR））。
从 2015 年 10 月至 2018 年 12 月，共纳入 77 例患者，共 120 处病变。平均年龄为 78.7±8.89 岁，58.5%为男性，18.2%为急性冠脉综合征（ACS）。患者至少有 2.0 个 LEADERS FREE 标准。所有病例均达到了血管造影成功。主要终点为 0%，未发生支架血栓形成。12 个月时的 MACE（可用于 52 例患者）为 3.8%，包括心脏死亡 0%、MI 0%和 TLR 3.8%。未发生严重出血事件（BARC3-5）或卒中和晚期支架血栓形成。
在 HBR 患者中，氯吡格雷作为 COBRA PzF NCS 植入后的 MAPT 是可行的，也是一种有吸引力的选择。1 年随访结果与良好的临床结果相关，需要大型随机研究来证实。
